United States Patent 5,679,709: Claim Scope, Coverage, and Landscape Implications
US Patent 5,679,709 has a claim set that is tight on a single chemical entity and then broad on downstream uses and dosage forms for autoimmune indications, while carving out systemic lupus erythematosus (SLE). The practical effect is a patent position that is strongest for (i) manufacture or import of the specific active ingredient, (ii) formulations that fall into the claimed dosage-unit and route ranges, and (iii) therapeutic use in autoimmune diseases defined by functional immunology outcomes, excluding SLE.
What is the claimed active ingredient and how narrow is the chemical scope?
Claim 1 is directed to one compound:
- N-(4-trifluoromethylphenyl-2-cyano-3-hydroxycrotonamide
- Defined by formula “##STR2##” (structure included in the patent record)
Scope consequences
- Single-entity structure constraint: The claim is not a Markush set of alternatives. It is a specific named compound with a specific structure.
- No explicit functional genericization: The claim does not read on “crotonamide derivatives” or “compounds of formula I” with substituent variability (based on the claim text provided). That keeps chemical coverage narrow.
- Salt coverage exists: Claim 2 extends to “physiologically tolerated salt” of the same compound, which typically covers routine acid addition salts and other pharmaceutically acceptable salts, without changing the underlying structure.
Claim-to-coverage mapping (core)
| Claim |
What it covers |
Scope strength |
| 1 |
The specific active compound (exact structure) |
Highest precision, narrow chemical perimeter |
| 2 |
Physiologically tolerated salts of claim 1 |
Moderate extension beyond free base |
How do the formulation claims limit or expand infringement risk?
Claims 3 to 5 define dosage and route.
Are the dosage ranges route-specific and unit-form constrained?
Yes. The formulation claims include explicit dosage quantities and solid form language.
Claim 3
- “A pharmaceutical composition comprising 10 to 200 mg of the compound of claim 1 in a solid dosage unit.”
Claim 4
- “A pharmaceutical composition comprising a compound of claim 1 and a physiologically acceptable carrier at a dosage of 1 to 30 mg for injection.”
Claim 5
- “A pharmaceutical composition comprising the compound of claim 1 at a dosage of 50 to 300 mg for rectal administration.”
Practical interpretation for infringement screening
- These claims are route- and dose-anchored. If a competitor uses the same active ingredient but departs materially from the claimed dose per unit and/or the named route (solid dosage unit vs injection vs rectal), it may avoid literal coverage.
- If a product uses different dose strengths but still contains a dosage range that overlaps, the exposure depends on unit dosing design (tablet strength, injection fill volume, rectal formulation gram mg content).
Route and dose coverage matrix
| Route |
Claim |
Dose per dosage unit (mg) |
Claim form constraint |
| Oral solid |
Claim 3 |
10 to 200 |
Solid dosage unit |
| Injectable |
Claim 4 |
1 to 30 |
With carrier; injection |
| Rectal |
Claim 5 |
50 to 300 |
Rectal administration |
What is the therapeutic use scope, and how broad is the disease definition?
Claims 6 to 8 are method-of-treatment claims that share the same disease restriction:
- Autoimmune diseases except systemic lupus erythematosus
They then define immunologic effects using functional language.
What is claimed for autoimmune disease treatment?
Claim 6
- “A method of treating autoimmune diseases except systemic lupus erythematosus”
- Administering an effective amount of the compound of claim 1 or a physiologically tolerable salt thereof.
What immunologic endpoints are claimed for method of reduction?
Claim 7
- “A method of reducing B-cell produced self-antibodies”
- Administering to a patient suffering an autoimmune disease except SLE.
What immunologic endpoint is claimed for T-cell proliferation?
Claim 8
- “A method of restoring the inhibited proliferation of T-lymphocytes to normal response levels”
- Administering to a patient suffering an autoimmune disease except SLE.
Scope consequences of functional endpoints
- Endpoint language creates flexibility: The claim does not require a specific biomarker assay name, but it does require the therapeutic intent/effect in the defined categories (B-cell self-antibodies reduction; T-lymphocyte proliferation normalization).
- Disease carve-out is explicit: SLE is excluded from the universe of covered autoimmune diseases.
Disease carve-out effect
- If a product’s clinical development targets SLE, it sits outside the explicit method claim language. That does not eliminate risk via other patents, but it reduces direct exposure to claims 6 to 8 as written.
How does salt language affect overall coverage?
Claim 2 provides salt protection. Salt claims can matter in practice because many formulations use acid addition salts or other pharmaceutically acceptable forms.
- Manufacturing exposure: If a competitor makes a salt form, they can still infringe claim 2 if the salt qualifies as “physiologically tolerated” and it is a salt of the claim 1 compound.
- Formulation exposure: For claims 3 to 5, salt form typically does not change route or unit dose structuring; the active amount still maps to claimed mg ranges (depending on whether mg is measured as compound free base vs salt).
- Method claims: Claims 6 to 8 cover administering the compound of claim 1 or a physiologically tolerable salt, so salt-based product labeling does not avoid method coverage.
What does this imply for the patent landscape (at the level of claim coverage)?
Because the claims provided are specific to US 5,679,709, the landscape analysis here focuses on where the patent is likely to block, and where it is likely to leave room.
Where the patent is most likely to be a barrier
- Any product that uses the exact active ingredient (claim 1) for autoimmune diseases other than SLE.
- Any product that targets immunologic mechanisms expressed in claims 7 or 8 if paired with administration to autoimmune patients excluding SLE.
- Formulation strategies that fall within dose per unit and route ranges:
- Oral solid unit: 10 to 200 mg per dosage unit
- Injection: 1 to 30 mg per injection unit
- Rectal: 50 to 300 mg per rectal administration unit
Where competitors have clearer design space
- SLE indication: the method claims explicitly exclude it.
- Non-overlapping dose/unit architecture: if a product uses different per-unit mg strengths and dosing regimens that are clearly outside the claimed ranges, literal formulation coverage may be weaker.
- Non-matching endpoints: if a development program uses a different therapeutic rationale not aimed at the B-cell self-antibody reduction or T-lymphocyte proliferation restoration theories, claim 7 and 8 may be less direct.
- Different actives: any substitute active ingredient outside the claim 1 structure is not covered by the provided claim set.
Claim strength assessment (practical, for diligence and clearance)
Chemical claim (Claim 1) strength
- Strong for certainty: a single compound definition reduces ambiguity in infringement analysis.
- Vulnerability: a competitor can potentially avoid chemical coverage by using different structures (no Markush breadth here).
Salt claim (Claim 2) strength
- Strong as a second entry point because most commercial forms are salts.
- Vulnerability: “physiologically tolerated” is a common qualifier, but it still requires that the salt is acceptable.
Formulation claims (Claims 3 to 5) strength
- Strong when dosage design matches.
- Vulnerable via formulation strategy:
- choose dose strengths outside ranges
- shift route
- redesign unit content so that mg per unit does not fall within the claim.
Method claims (Claims 6 to 8) strength
- Strong for labeling and clinical intent:
- Sufficient if the method is used in the claimed disease universe
- Strong if trials and labeling articulate or rely on the claimed immunologic outcomes.
- Vulnerable:
- SLE carve-out removes that label space.
- Non-identical therapeutic effect or differing patient population may reduce direct fit.
What to look for in freedom-to-operate (FTO) work against US 5,679,709
Even without examining the prosecution history, the provided claim text yields a checklist for dossier and product design review:
Active ingredient verification
- Confirm whether the product contains the exact N-(4-trifluoromethylphenyl-2-cyano-3-hydroxycrotonamide free base or a salt.
- Confirm whether the mg labeling is expressed as active compound basis that aligns with claim ranges.
Route and dose per unit alignment
- For oral solid products: check mg per tablet/capsule against 10 to 200 mg.
- For injection: check mg per injection unit against 1 to 30 mg.
- For rectal: check mg per administration against 50 to 300 mg.
Indication and trial endpoint alignment
- Ensure the intended autoimmune indication is not SLE.
- Check whether clinical rationale, endpoints, or mechanistic language aligns with:
- reducing B-cell produced self-antibodies (Claim 7)
- restoring T-lymphocyte proliferation (Claim 8)
Key Takeaways
- US 5,679,709 centers on a single specified compound (Claim 1) and its physiologically tolerated salts (Claim 2).
- Formulation coverage is route- and dose-anchored: oral solid (10 to 200 mg per solid unit), injection (1 to 30 mg), rectal (50 to 300 mg).
- Therapeutic coverage is method-of-use for autoimmune diseases excluding SLE, with additional functional endpoints tied to B-cell self-antibodies and T-lymphocyte proliferation normalization.
- The strongest FTO risk points are products that (i) use the exact active ingredient, (ii) maintain unit doses within the claimed ranges, and (iii) pursue autoimmune indications other than SLE with endpoint logic aligned to claims 7 and 8.
FAQs
1) Does US 5,679,709 cover systemic lupus erythematosus (SLE)?
No. Claims 6 to 8 expressly exclude systemic lupus erythematosus from the autoimmune disease universe.
2) If a product uses the same active ingredient but changes the route, is it automatically non-infringing?
It reduces risk against the specific formulation claims (3 to 5), but method claims (6 to 8) can still apply if the indication and administration fall within the autoimmune disease definition excluding SLE.
3) Can a competitor avoid Claim 3 by changing tablet strengths?
If tablet strengths are designed so that the active amount per solid dosage unit does not fall within 10 to 200 mg, literal coverage under Claim 3 is less likely.
4) Are salts covered even if the free base is avoided?
Yes. Claim 2 covers physiologically tolerated salts of the claim 1 compound.
5) Are B-cell and T-cell claims limited to specific assays or biomarkers?
The claims are tied to the functional endpoints (reducing self-antibodies; restoring T-lymphocyte proliferation), without requiring named assay formats in the claim text provided.
References
[1] United States Patent US 5,679,709, claims 1-8 (as provided in the prompt).
